Medpace (NASDAQ:MEDP) CEO Sells $3,328,867.02 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 5,534 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $601.53, for a total value of $3,328,867.02. Following the completion of the sale, the chief executive officer directly owned 633,412 shares of the company’s stock, valued at approximately $381,016,320.36. The trade was a 0.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Medpace Stock Down 1.4%

Shares of NASDAQ:MEDP traded down $8.52 during midday trading on Wednesday, hitting $596.98. The stock had a trading volume of 310,338 shares, compared to its average volume of 355,204. The company has a market cap of $16.66 billion, a P/E ratio of 34.99, a PEG ratio of 2.69 and a beta of 1.15. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The business’s 50-day simple moving average is $528.36 and its 200-day simple moving average is $491.85.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Institutional Investors Weigh In On Medpace

A number of large investors have recently added to or reduced their stakes in MEDP. NewEdge Advisors LLC lifted its position in shares of Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after acquiring an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Medpace by 3.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after purchasing an additional 3,010 shares during the period. Geneos Wealth Management Inc. increased its position in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the period. Sivia Capital Partners LLC acquired a new position in Medpace in the second quarter valued at about $296,000. Finally, M&T Bank Corp raised its stake in Medpace by 3.4% in the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after purchasing an additional 31 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on MEDP shares. Leerink Partners set a $620.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and boosted their price target for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th. BMO Capital Markets upped their price objective on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Truist Financial lifted their target price on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Two investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.